Experiments In Tumor-bearing Mice Research Articles

Enhancing Effects of Theanine Liposomes as Chemotherapeutic Agents for Tumor Therapy.

Chemotherapy is one of the most effective methods of treating tumors in clinical study currently, but drug side effects usually are unbearable to the patient, which also makes it difficult to continue chemotherapy. Enhanced drug efficacy and reduced drug side effects are the main strategies for tumor therapy. Herein, based on biochemical regulation, theanine liposomes were designed to adjuvant doxorubicin (DOX) therapy, which can reduce the adverse reactions and enhance the effect of DOX. Stigmasterol was applied instead of traditional cholesterol for reducing the risk of cardiovascular disease. The as-prepared theanine liposomes by two methods had optimal sizes (154.8 and 169.0 nm), which can effectively accumulate in tumor tissues. In vitro experiments demonstrated that the theanine liposomes had a good effect of sustaining drug release. Cell uptake indicated that the presence of theanine can effectively inhibit glutathione (GSH) levels in cells and increase the uptake of DOX. In tumor bearing mice experiments, the combination of the theanine liposomes and DOX showed a better tumor inhibitory effect with a smaller tumor volume (2.7 fold) compared with that of the free DOX group. Meanwhile, under the mediation of theanine, the amount of doxorubicin was greatly reduced to achieve the same therapeutic effect, and the side effects of the drug were largely inhibited. Therefore, theanine liposomes have great application potential in tumor chemotherapy.

Positive feedback nanoamplifier responded to tumor microenvironments for self-enhanced tumor imaging and therapy

Targeted activation or enhancement is an attractive strategy in the design of nano-theranostics. However, the responsiveness of the nanoagents is restricted by the limited levels of intra-tumor stimuli. Herein, we constructed a positive feedback nanoamplifier by encapsulating glucose oxidase (GOx) in the ferric ions contained metal organic framework (MIL-100), and coating the nanoparticles with polydopamine modified hyaluronic acid (HA-PDA). The mechanism of action of the ensuing nanoamplifiers was three pronged: 1) the high intra-tumor acidity accelerated the release of GOx, which consumed endogenous glucose and “starved” the tumors, in addition to aggravating the local acidity and H2O2 levels; 2) the hydroxyl radicals (·OH) generated from the Fenton-like reaction between MIL-100 with H2O2 contributed to the chemodynamic tumor therapy and augmented the O2 microenvironment, which could be speeded up under acid condition; 3) the oxygen (O2) produced in the Fenton-like reaction relieved the intra-tumor hypoxia and ensured the enzymatic reaction of GOx, along with augmenting the photoacoustic signal of nanoamplifier. Preliminary experiments in tumor bearing mice showed that the nanoamplifier not only boosted the local acidity/H2O2/O2 levels in tumor site to successfully suppress the growth of tumors through the self-enhanced chemodynamic/starving therapy, but also achieved the photoacoustic imaging of tumors. Taken together, this novel nanoamplifier with the abilities of self-enhanced tumor imaging and therapy is a promising entrant in the field of anti-tumor theranostics.

A pH-responsive prodrug delivery system self-assembled from acid-labile doxorubicin-conjugated amphiphilic pH-sensitive block copolymers

The development of intelligent drug delivery system that can efficiently deliver doxorubicin (DOX) to tumor site with controlled drug release performance and enhanced therapeutic efficacy is of great significance for cancer chemotherapy. In this report, a nano-prodrug system was prepared successfully by conjugating DOX to pH-sensitive amphiphilic diblock copolymer poly (ethylene glycol) methyl ether‑b‑poly (β‑amino esters) through acid-labile cis‑aconityl moiety (mPEG-b-PAE-cis-DOX). The resultant complex copolymer-drug was able to self-assemble into polymeric micelles (PMs) in an aqueous solution at low concentration, and the critical micelle concentration (CMC) was 3.6 mg/L which was increased as decrease of pH value. H-nuclear magnetic resonance (1H NMR), Fourier transform infrared (FT-IR), dynamic light scattering (DLS), transition electron microscopy (TEM), and classic acid-base titration were combined to confirm and characterize the chemical structure of the copolymer/drug conjugates and the physicochemical properties of the prodrug system. The DOX loading capacity, drug delivery and therapeutic efficacy of the conjugates were evaluated in vitro and in vivo. Notably, the antitumor experiments in tumor-bearing mice demonstrated that the pH-responsive nano-prodrug system effectively enhanced the therapeutic efficacy in comparison to free drug. All above results suggested that pH-responsive prodrug system has the potential to be effective carrier for the DOX delivery and pH-triggered controlled release.

Endosome Targeting meso-Tetraphenylchlorin-Chitosan Nanoconjugates for Photochemical Internalization.

Four amphiphilic covalently linked meso-tetraphenylchlorin-chitosan nanoconjugates were synthesized and evaluated for use in photochemical internalization (PCI) in vitro and in vivo. The synthetic protocol for the preparation of two different hydrophobic chlorin photosensitizers, 5-(4-aminophenyl)-10,15,20-triphenylchlorin and 5-(4-carboxyphenyl)-10,15,20-triphenylchlorin, was optimized. These monofunctional photosensitizers were covalently attached to carrier chitosan via silyl-protected 3,6-di-O-tert-butyldimethylsilyl-chitosan (Di-TBDMS-chitosan) with 0.10 degree of substitution per glucosamine (DS). Hydrophilic moieties such as trimethylamine and/or 1-methylpiperazine were incorporated with 0.9 DS to give fully water-soluble conjugates after removal of the TBDMS groups. A dynamic light scattering (DLS) study confirmed the formation of nanoparticles with a 140-200 nm diameter. These nanoconjugates could be activated at 650 nm (red region) light, with a fluorescence quantum yield (ΦF) of 0.43-0.45, and are thus suitable candidates for use in PCI. These nanoconjugates were taken up and localized in the endocytic vesicles of HCT116/LUC human colon carcinoma cells, and upon illumination they substantially enhanced plasmid DNA transfection. The nanoconjugates were also evaluated in preliminary in vivo experiments in tumor-bearing mice, showing that the nanoconjugates could induce a strong photodynamic therapy (PDT) and also PCI effects in treatment with bleomycin.

Fast dynamic electron paramagnetic resonance (EPR) oxygen imaging using low-rank tensors

Hypoxic tumors are resistant to radiotherapy, motivating the development of tools to image local oxygen concentrations. It is generally believed that stable or chronic hypoxia is the source of resistance, but more recent work suggests a role for transient hypoxia. Conventional EPR imaging (EPRI) is capable of imaging tissue pO2in vivo, with high pO2 resolution and 1mm spatial resolution but low imaging speed (10min temporal resolution for T1-based pO2 mapping), which makes it difficult to investigate the oxygen changes, e.g., transient hypoxia. Here we describe a new imaging method which accelerates dynamic EPR oxygen imaging, allowing 3D imaging at 2 frames per minute, fast enough to image transient hypoxia at the “speed limit” of observed pO2 change. The method centers on a low-rank tensor model that decouples the tradeoff between imaging speed, spatial coverage/resolution, and number of inversion times (pO2 accuracy). We present a specialized sparse sampling strategy and image reconstruction algorithm for use with this model. The quality and utility of the method is demonstrated in simulations and in vivo experiments in tumor bearing mice.

Constructing aptamer anchored nanovesicles for enhanced tumor penetration and cellular uptake of water soluble chemotherapeutics

Polymersomes represent a promising pharmaceutical vehicle for the delivery of hydrophilic therapeutic agents. However, modification of polymersomes with molecules that confer targeting functions remains challenging because of the strict requirements regarding the weight fractions of the hydrophilic and hydrophobic block polymers. In this study, based on the compatibility between cholesterol and polymeric carriers, polymersomes self-assembled by amphiphilic graft polyphosphazenes were endowed with a targeting function by incorporating the cholesterol-linked aptamer through a simple dialysis method. The aqueous interior of the polymersomes was employed to encapsulate water-soluble doxorubicin hydrochloride. In vivo experiments in tumor-bearing mice showed that the aptamer-anchored vesicle targeted accumulation at the tumor site, favorable penetration through tumor tissue, and incremental endocytosis into tumor cells. Correspondingly, the aptamer-anchored vesicle decreased systemic toxicity and effectively suppressed the growth of subcutaneous MCF-7 xenografts. These findings suggested that vesicles modified with targeted groups via hydrophobic supermolecular interactions could provide a platform for selective delivery of hydrophilic drug. Statement of SignificancePolymersomes have represented a promising type of pharmaceutical vehicles due to their predominant physical properties. However, it is still a challenge to endow polymersomes with active target function because of strict requirements of the weight fractions of hydrophilic polymer block to hydrophobic one. In this research, by taking advantage of the supermolecular interactions between amphiphilic graft polyphosphazene and cholesterol which was linked to aptamer AS1411, we prepared a targeted functional polymersome (PEP-DOX·HCl-Ap) through a simple method with high loading of water soluble anti-cancer drug doxorubicin hydrochloride. The in vivo experiments in MCF-7 tumor-bearing mice demonstrated several advantages of PEP-DOX·HCl-Ap vesicle such as prolonged circulation time in blood, targeted accumulation at tumor site, permeation through the tumor tissue and incremental endocytosis by tumor cells, which consequently resulted in the significantly improved anti-cancer efficacy. Moreover, this novel polymersome designed in this study has built a research platform to achieve targeted delivery of hydrophilic chemotherapeutics for cancer therapy.

Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy.

Blockade of the protein-protein interaction between the transmembrane protein programmed cell death protein 1 (PD-1) and its ligand PD-L1 has emerged as a promising immunotherapy for treating cancers. Using the technology of mirror-image phage display, we developed the first hydrolysis-resistant D-peptide antagonists to target the PD-1/PD-L1 pathway. The optimized compound (D) PPA-1 could bind PD-L1 at an affinity of 0.51 μM in vitro. A blockade assay at the cellular level and tumor-bearing mice experiments indicated that (D) PPA-1 could also effectively disrupt the PD-1/PD-L1 interaction in vivo. Thus D-peptide antagonists may provide novel low-molecular-weight drug candidates for cancer immunotherapy.

Redox- and pH-Sensitive Polymeric Micelles Based on Poly(β-amino ester)-Grafted Disulfide Methylene Oxide Poly(ethylene glycol) for Anticancer Drug Delivery

In this report, a redox- and pH-sensitive poly(β-amino ester)-grafted disulfide methylene oxide poly(ethylene glycol) (PAE-g-DSMPEG) was synthesized, and it showed not only a sharp pH-dependent assembly–disassembly transition but also a quick shell shading in a high concentration of reducing agent by Michael addition polymerization. 1H NMR, dynamic light scattering, and transition electron microscopy were combined to characterize the redox- and pH-responsiveness in various triggered conditions. The hydrophobic drug doxorubicin (DOX) was used as the model drug to investigate the encapsulation and delivery ability of polymeric micelles, in both in vitro and in vivo experiments. Notably, antitumor experiments in tumor-bearing mice showed that DOX-loaded polymeric micelles effectively enhanced the therapeutic efficacy in comparison to free-DOX. These results were further confirmed by histopathological examinations. Taken together, the results suggested that PAE-g-DSMPEG could be a potential hydrophobic drug d...

Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantation‑induced tumor growth.

Previous studies revealed that Kanglaite (KLT) exhibits antitumor and immunomodulatory activities. In the present study, we show that KLT treatment stimulated the immune response by increasing the number of T cells and natural killer (NK) cells in the blood of hepatocellular carcinoma (HCC) patients. Experiments in tumor-bearing mice were further designed in order to explore the effects of KLT on the immune system and the underlying molecular mechanisms. The results showed that KLT improves the tumor cell transplantation-induced reduction in the serum level of the cytokines IFN‑γ and IL‑2, and rescues the levels of CD4+ T cells in host mice. These events enhanced the cytotoxic activities of natural killer and CD8+ T cells against the hepatic HepG2 cancer cells. KLT administration further increased the mRNA level of certain nuclear factor κB (NF‑κB)‑responsive genes in CD4+ cells. The chromatin immunoprecipitation assay showed that KLT increases the association of the NF-κB p65 subunit to the promoter regions of interleukin (IL)-2- and B-cell lymphoma (Bcl)-2-encoding genes in CD4+ T cells. Our study demonstrated that KLT is the main active ingredient of coix seed exhibiting anticancer and immunomodulatory properties. Induction of NF-κB‑mediated gene transcription in CD4+ T cells is involved in the immunomodulatory activity of KLT.

Tumor-targeting nanogel that can function independently for both photodynamic and photothermal therapy and its synergy from the procedure of PDT followed by PTT

A dual-function nano-system for synergistic photodynamic therapy (PDT) and photothermal therapy (PTT) was constructed. Gold nanorods (GNRs) as a PTT agent and chlorin e6 (Ce6) as a photosensitizer (PS) for PDT were loaded into a chitosan-functionalized, Pluronic-based nanogel that was proven to be an efficient delivery vehicle to the tumor site in vivo. Previously reported combined therapy systems relied on quenching and de-quenching of PS for PDT upon thermo-impact of PTT, thus only PTT followed by PDT procedure was possible. In contrast, the present dual-acting system has no quenching between PS and GNRs by preventing direct contact and self-aggregation of photo-sensitizers, allowing independent PDT or PTT procedure. In both in vitro cell culture and in vivo tumor-bearing mice experiments, a remarkably enhanced tumor ablation compared to the treatment of PDT or PTT only was observed by the treatment of PDT followed by PTT, but not significantly by the treatment of PTT followed by PDT. Thus, the present study demonstrated the synergistic effect of PDT and PTT in a sequence-dependent manner, and our system is a promising dual function nano system to achieve the enhanced phototherapy in vivo.

Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts

Pharmacokinetic-pharmacodynamic (PK-PD) models able to predict the action of anticancer compounds in tumor xenografts have an important impact on drug development. In case of anti-angiogenic compounds, many of the available models show difficulties in their applications, as they are based on a cell kill hypothesis, while these drugs act on the tumor vascularization, without a direct tumor cell kill effect. For this reason, a PK-PD model able to describe the tumor growth modulation following treatment with a cytostatic therapy, as opposed to a cytotoxic treatment, is proposed here. Untreated tumor growth was described using an exponential growth phase followed by a linear one. The effect of anti-angiogenic compounds was implemented using an inhibitory effect on the growth function. The model was tested on a number of experiments in tumor-bearing mice given the anti-angiogenic drug bevacizumab either alone or in combination with another investigational compound. Nonlinear regression techniques were used for estimating the model parameters. The model successfully captured the tumor growth data following different bevacizumab dosing regimens, allowing to estimate experiment-independent parameters. A combination model was also developed under a 'no-interaction' assumption to assess the effect of the combination of bevacizumab with a target-oriented agent. The observation of a significant difference between model-predicted and observed tumor growth curves was suggestive of the presence of a pharmacological interaction that was further accommodated into the model. This approach can be used for optimizing the design of preclinical experiments. With all the inherent limitations, the estimated experiment-independent model parameters can be used to provide useful indications for the single-agent and combination regimens to be explored in the subsequent development phases.

Towards new boron carriers for boron neutron capture therapy: Metallacarboranes bearing cobalt, iron and chromium and their cholesterol conjugates

A method for the synthesis of cholesterol–metallacarborane conjugates bearing cobalt, iron and chromium was developed. Effective incorporation of the cholesterol conjugate bearing cobalt into liposome membrane was revealed. Using the metallacarborane-encrusted liposomes as boron delivery system in vivo biodistribution experiments in tumor-bearing mice, high accumulation and selective delivery of boron into tumor tissues was observed. The results demonstrate that the cholesterol–metallacarborane conjugates can be considered as a potential candidate for boron delivery vehicle in BNCT.

Assessment of DNA Damage in Target Tumor Cells after Thermoablation in Mice

To determine the effects of temperature on cell death for cells in culture and to compare these effects with the results of in vivo experiments in which heating is induced in mice with implanted human adenocarcinoma by using magnetic methods. Experimentation was approved by the regional animal care committee. Human adenocarcinoma cells (MX-1) and human fibroblasts (HTB-125) were exposed to defined temperatures of 45 degrees -90 degrees C for 4 minutes. Single- and double-strand DNA breaks (expressed as a percentage of the total DNA in tail) were identified by using the alkaline comet assay, and cell survival was determined by using the cloning assay and trypan blue exclusion. For in vivo experiments, MX-1 tumors were implanted into 14 mice. Magnetic heating at temperatures of 59 degrees -96 degrees C was subsequently performed by injecting magnetic material into the tumor (7 mg +/- 3 [+/- standard deviation] magnetite per tumor) and applying an alternating magnetic field (8.8 kA/m; 400 kHz) for 4 minutes. The efficiency of the temperature-dependent induction of DNA damage in isolated tumor cells was quantified and compared with that in cultured cells. Results of experiments with cell cultures revealed a strong correlation between DNA damage, cell survival, and temperature, as determined with the cloning assay and trypan blue exclusion. The threshold thermoablasive temperature for tumor cell elimination was found to be 55 degrees-60 degrees C. Moreover, a strong impairment in cell survival was found when damaged DNA accounted for more than 50% of the total DNA. The heating sensitivities of malignant and nonmalignant cells did not differ. After the magnetic heating of tumors in vivo to temperatures of up to 96 degrees C (rectal temperatures between 27 degrees C +/- 2 and 29 degrees C +/- 2), isolated tumor cells showed a mean of 71.9% +/- 24.5 of total DNA in the tail per cell compared with nontreated tumors, which showed 8.0% +/- 3.1. There appears to be a threshold temperature for the induction of irreversible DNA damage. This is reflected by the results of in vivo experiments in tumor-bearing mice after high temperatures were applied to tumors by using magnetic heating.

Recent advances in pharmacologic study of natural anticancer agents in China

In this paper a number of anticancer agents of natural origin will be presented. Hydroxycamptothecin (HCPT) was found to produce a strong inhibitory action on a variety of animal tumors. It is also effective for treatment of patients with gastric carcinoma, liver carcinoma, tumor of head and neck or leukemia. Pharmacologic studies showed that it could depress S phase of tumor cells significantly and cause formation of cellular chromatid breaks. By means of alkaline elution and nick translation methods it has been proved that HCPT induced DNA single strand breaks remarkably. Homoharringtonine (HHRT) was shown to be effective against acute leukemia. Recent experiments in tumor-bearing mice indicated that (HHRT) could diminish tumor metastasis. Using molecular hybridization technique it was demonstrated that (HHRT) decreased the content of c-myc RNA in the cytoplasm but not in the nuclei. Lycobetaine (LBT) possessed strong inhibitory effects on a number of ascites tumors. In clinical trials it was effective against ovarian and gastric carcinomas. It is able to intercalate into DNA. Oxalysine (OXL) is a new antibiotic and shown to be effective against tumor metastatis. When used in combination with 5-FU, its anticancer action could be enhanced. Other natural compounds such as indirubin, beta-elemene, irisquinone, oridonine, norcantharidin and PSP have been also found to possess antitumor action.

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

The rapid clearance of circulating liposomes from the bloodstream, coupled with their high uptake by liver and spleen, has thus far been an obstacle to any attempts at targeting to tumors. We have assessed the impact of liposome composition on their clearance from the circulation in normal and tumor-bearing mice and on their uptake by tumors and various normal tissues. By selective changes in lipid composition, while maintaining a mean particle diameter of approximately equal to 100 nm, we have achieved up to a 60-fold increase in the fraction of recovered dose present in blood 24 hr after i.v. injection. Concomitantly, there was a decrease by a factor of 4 of the recovered dose localizing in the liver and spleen, the major organs of the reticuloendothelial system. Parallel experiments in tumor-bearing mice demonstrated a 25-fold increase of the liposome concentration in the tumor when formulations with long and short blood residence time were compared. The most favorable results were obtained with liposomes containing a small molar fraction of a negatively charged glycolipid, such as monosialoganglioside or phosphatidylinositol, and a solid-phase neutral phospholipid as the bulk component. The bio-distribution of such formulations is of considerable therapeutic potential in cancer for increasing the concentration of cytotoxic agents in tumors while minimizing the likelihood of toxicity to the reticuloendothelial system.

Modification of in vivo methotrexate antitumor effect in L1210 leukemia by induced impairment of purine salvage

Studies with murine cells have shown that the antitumor action of methotrexate (MTX) may be through a purineless mechanism. If the MTX effect depends, in part, on inhibition of de novo purine synthesis, then the ability of tumor cells to salvage available purine precursors could reduce the cell kill. In the present study, we produced L1210 murine leukemia mutants with impaired purine salvage to determine whether this would affect responsiveness to MTX. Mutant lines L1210/MP, L1210/FAMP, and L1210/555 were produced by developing resistance to the purine analogs 6-mercaptopurine (6-MP), 6-MP + 2-fluoroadenine (2-FA), and 6-MP + 2-FA + 6-methylmercaptopurine riboside respectively. The purine salvage capability of the cell lines was confirmed in vitro by testing the ability of various purines to reverse the growth inhibitory and biochemical effects of MTX in the presence of thymidine. Dose-response curves demonstrated identical in vitro MTX sensitivity for L1210/MP, L1210/FAMP, and the parent line, L1210/S. Despite identical in vitro MTX sensitivity, the cell lines L1210/MP and L1210/FAMP displayed increased sensitivity to the biochemical effects of MTX in an in vivo model, and this was translated into enhanced sensitivity as measured by survival experiments in tumor-bearing mice. The results indicate that impairment of purine salvage sensitizes cells to the antitumor effect of MTX in vivo. This has implications for the clinical use of MTX in view of the variety of rescue techniques that is available.